

[Hyoscine butylbromide](#)

Essential medicine status

Section:

[2. Medicines for pain and palliative care](#) [2.3. Medicines for other common symptoms in palliative care](#)

ATC codes: [A03BB01](#)

Indication

Palliative care ICD11 code: [QC7A](#)

Medicine type

Chemical agent

List type

Core

Formulations

Parenteral > General injections > unspecified: 20 mg per mL injection

EML status history

First added in 2013 ([TRS 985](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Hyoscine butylbromide](#)

DrugBank

[Hyoscine butylbromide \(Scopolamine butylbromide\)](#)

Summary of evidence and Expert Committee recommendations



Following a review of medicines for palliative care by the Expert Committee in 2013, hyoscine butylbromide was added to the core list of the EML for management of respiratory secretions in patients receiving palliative care. Although the evidence for the benefit to the patient of the use of antimuscarinic agents in prevention of accumulation of respiratory tract secretions during the dying phase was acknowledged as weak by the Expert Committee, the inclusion of hyoscine butylbromide (which, in contrast to the hydrobromide included for children, does not cross the blood-brain barrier) was supported.